F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
Pietro Lampertico,Kosh Agarwal,Thomas Berg,Maria Buti,Harry L.A. Janssen,George V. Papatheodoridis,Fabien Zoulim,Frank Tacke +7 more
TL;DR: This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection, and future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.
Journal ArticleDOI
EASL Clinical Practice Guidelines: Management of chronic hepatitis B
C.P.G.P.P. Marcellin,G.M. Dusheiko,Fabien Zoulim,Rafael Esteban,Stephanos J. Hadziyannis,Pietro Lampertico,M.P. Manns,Daniel Shouval,Cihan Yurdaydin,R.A. Craxi,Xavier Forns,Darius Moradpour,Jean-Michel Pawlotsky,Jörg Petersen,H.W.F. Easl +14 more
TL;DR: The objective of these EASL Clinical Practice Guidelines is to update recommendations for the optimal management of chronic hepatitis B (CHB) and the CPGs do not focus on prevention and vaccination.
Journal ArticleDOI
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness
Lieven Stuyver,Sija De Gendt,Caroline Van Geyt,Fabien Zoulim,Michael W. Fried,Raymond F. Schinazi,Rudi Rossau +6 more
TL;DR: The hepatitis B virus (HBV) genotype was determined in a total of 121 plasma samples collected in France and the US from patients chronically infected with HBV as discussed by the authors, and subsequent phylogenetic analysis of the complete genome and the individual open reading frames, showed that the virus isolate from these samples was 3248 bp long and, phylogenetically, did not cluster with any of the known genotypes.
Journal ArticleDOI
Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases
TL;DR: New nucleoside analogues and associated compounds that are currently in preclinical or clinical development for the treatment of cancer and viral infections, and that aim to provide increased response rates and reduced side effects are reviewed.
Journal ArticleDOI
Persistence of cccDNA During the Natural History of Chronic Hepatitis B and Decline During Adefovir Dipivoxil Therapy
Bettina Werle-Lapostolle,Scott Bowden,Stephen Locarnini,Karsten Wursthorn,Karsten Wursthorn,Jörg Petersen,Jörg Petersen,George K. K. Lau,Christian Trepo,Patrick Marcellin,Zachary Goodman,William E. Delaney,Shelly Xiong,Carol L. Brosgart,Shan-Shan Chen,Craig S. Gibbs,Fabien Zoulim +16 more
TL;DR: cccDNA persists throughout the natural history of chronic hepatitis B, even in patients with serologic evidence of viral clearance, and long-term ADV therapy significantly decreased cccDNA levels by a primarily noncytolytic mechanism.